Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea
Treatment Registry of Alecensa in Korean Patients With Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Busan, Korea, Republic of, 49241
- Pusan National University Hospital
-
Busan, Korea, Republic of, 49201
- Dong-A University Hospital
-
Busan, Korea, Republic of, 47392
- Inje University Busan Paik Hospital
-
Busan, Korea, Republic of, 49267
- Kosin University Gospel Hospital
-
Busan, Korea, Republic of
- Dongnam Institute of Radiological & Medical Sciences
-
Cheongju-si, Korea, Republic of, 28644
- Chungbuk National University Hospital
-
Daegu, Korea, Republic of, 41404
- Kyungpook National University Chilgok Hospital
-
Daegu, Korea, Republic of, 41931
- Keimyung University Dongsan Medical Center
-
Daegu, Korea, Republic of, 42472
- Daegu Catholic University Medical Center
-
Daejeon, Korea, Republic of, 35365
- Konyang University Hospital
-
Gangwon-do, Korea, Republic of, 26426
- Yonsei University Wonju Severance Christian Hospital
-
Gyeonggi-do, Korea, Republic of, 13496
- CHA Bundang Medical Center
-
Gyeonggi-do, Korea, Republic of, 16247
- St. Vincent's Hospital
-
Gyeonggi-do, Korea, Republic of, 11765
- Uijeongbu St. Mary's Hospital
-
Gyeonggi-do, Korea, Republic of, 14068
- Hallym University Sacred Heart Hospital
-
Gyeonggi-do, Korea, Republic of, 14647
- Bucheon St Mary's hospital
-
Gyeonggi-do, Korea, Republic of, 10380
- Inje University Ilsan Paik Hospital
-
Gyeongsangnam-do, Korea, Republic of, 50612
- Pusan National University Yangsan Hospital
-
Incheon, Korea, Republic of, 21565
- Gachon University Gil Medical Center
-
Incheon, Korea, Republic of, 22332
- Inha University Hospital
-
Incheon, Korea, Republic of, 21431
- Catholic Univ. of Incheon St.Mary's Hospital
-
Jeollabuk-do, Korea, Republic of, 54907
- Chonbuk National University Hospital
-
Jeollanam-do, Korea, Republic of, 58128
- Chonnam National University Hwasun Hospital
-
Seoul, Korea, Republic of, 03722
- Severance Hospital
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
Seoul, Korea, Republic of, 02447
- Kyung Hee University Hospital
-
Seoul, Korea, Republic of, 02841
- Korea University Anam Hospital
-
Seoul, Korea, Republic of, 07985
- Ewha Womans University Mokdong Hospital
-
Seoul, Korea, Republic of, 08308
- Korea University Guro Hospital
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of, 03181
- Kangbuk Samsung Hospital
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University
-
Seoul, Korea, Republic of, 06273
- Gangnam Severance Hospital
-
Seoul, Korea, Republic of, 05278
- Gangdong Kyung Hee University Hospital
-
Seoul, Korea, Republic of, 01757
- Inje University, Sanggye-Paik Hospital
-
Seoul, Korea, Republic of, 140-743
- Soon Chun Hyang University Hospital; Department of Pulmonology and Allergy
-
Wonju-Si, Korea, Republic of, 220-701
- Yonsei University Wonju Severance Christian Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects who are administered alectinib at physician's discretion and fall into the approved indication in Korea.
Exclusion Criteria:
- Hypersensitivity to alectinib or any ingredient of alectinib;
- Pregnant or lactating women;
- Pediatric subjects (age </=18 years);
- Due to the presence of lactose, subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take alectinib.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Alectinib
Participants with ALK-positive, locally advanced or metastatic non-small cell lung cancer, who are treated with alectinib in accordance with local clinical practice and local labeling, are observed in this study.
|
According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants with Adverse Events (AEs)
Time Frame: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Preexisting conditions which worsen during a study are also considered as AEs.
All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
|
Up to approximately 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Response Rate (ORR)
Time Frame: Up to approximately 3 years
|
ORR will be determined according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 as assessed by physicians under routine clinical practice.
Overall response rate was defined as the percentage of participants who had any evidence of Complete Response (CR) or Partial Response (PR): CR is defined as the disappearance of all target lesions and all nodes with short axis <10 millimeter (mm); PR is defined as >/=30% decrease in the sum of the longest diameter of target lesions.
Target lesions are those lesions with longest diameter >/=10 mm and limits that are sufficiently well defined for their measurement to be considered reliable.
Lymph nodes are target lesions if short-axis measures >/=15 mm.
Maximum number of selected target lesions is 5 per participant and 2 per organ.
Overall Response (OR) = CR + PR.
|
Up to approximately 3 years
|
|
Complete Response (CR)
Time Frame: Up to approximately 3 years
|
CR will be determined according to RECIST v1,1 as assessed by physicians under routine clinical practice and is defined as disappearance of all target lesions and all nodes with short axis <10 mm.
Target lesions are those lesions with longest diameter >/=10 mm and limits that are sufficiently well defined for their measurement to be considered reliable.
Lymph nodes are target lesions if short-axis measures >/=15 mm.
Maximum number of selected target lesions is 5 per participant and 2 per organ.
|
Up to approximately 3 years
|
|
Percentage of Participants with Partial Response (PR)
Time Frame: Up to approximately 3 years
|
PR will be determined according to RECIST v1.1 as assessed by physicians under routine clinical practice and is defined as >/=30% decrease in the sum of the longest diameter of target lesions.
Target lesions are those lesions with longest diameter >/=10 mm and limits that are sufficiently well defined for their measurement to be considered reliable.
Lymph nodes are target lesions if short-axis measures >/=15 mm.
Maximum number of selected target lesions is 5 per participant and 2 per organ.
|
Up to approximately 3 years
|
|
Percentage of Participants with Stable Disease (SD)
Time Frame: Up to approximately 3 years
|
SD will be determined according to RECIST v1.1 as assessed by physicians under routine clinical practice and is defined as neither response nor progression.
Response is defined as at least >/=30% decrease in the sum of the longest diameter of target lesions.
Progression is defined as >/= 20% increase in the sum of target lesions taking as reference the smallest sum measured during follow-up and >/= 5 mm in absolute value.
Target lesions are those lesions with longest diameter >/=10 mm and limits that are sufficiently well defined for their measurement to be considered reliable.
Lymph nodes are target lesions if short-axis measures >/=15 mm.
Maximum number of selected target lesions is 5 per participant and 2 per organ.
|
Up to approximately 3 years
|
|
Percentage of Participants with Progressive Disease (PD)
Time Frame: Up to approximately 3 years
|
PD will be determined according to RECIST v1.1 as assessed by physicians under routine clinical practice and is defined as >/=20% increase in the sum of target lesions taking as reference the smallest sum measured during follow-up and >/= 5 mm in absolute value.
Target lesions are those lesions with longest diameter >/=10 mm and limits that are sufficiently well defined for their measurement to be considered reliable.
Lymph nodes are target lesions if short-axis measures >/=15 mm.
Maximum number of selected target lesions is 5 per participant and 2 per organ.
|
Up to approximately 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ML30132
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.